Abstract
Functional delivery of botulinum toxin A (BTA) by proprietary Flex-PADs (soluble microneedle arrays) to treat hyperhidrosis offers the promise of a patient friendly-alternative to the current multitude of intradermal injections. Administration of BTA-loaded Flex-PADs to mouse footpads in split-body studies led to similar sweat inhibition as traditional intradermal injections, as measured by a modified starch/iodine assay. This novel modification allows visualization of sweat activity from individual sweat glands in both human and mouse skin. In addition to hyperhidrosis and aesthetic applications, Flex-PAD administration can also be used to treat painful genodermatoses such as pachyonychia congenita (PC) and epidermolysis bullosa simplex (EBS), which have been shown by others to be responsive to BTA treatment but require heavy anesthesia and/or sedation. These findings represent an encouraging first step toward bringing this patient-friendly delivery alternative to the clinic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
